Workflow
润都股份(002923) - 2020 Q3 - 季度财报
Rundu PharmaRundu Pharma(SZ:002923)2020-10-27 16:00

Financial Performance - Net profit attributable to shareholders increased by 3.66% to ¥34,481,781.88 for the current period[7] - Operating income decreased by 7.66% to ¥303,163,230.88 compared to the same period last year[7] - Basic earnings per share rose by 5.56% to ¥0.19[7] - The total profit for the period was CNY 37,976,738.88, down from CNY 40,301,426.03, reflecting a decline of about 5.4%[44] - Net profit for Q3 2020 was CNY 34,481,781.88, slightly up from CNY 33,264,994.49 in the same period last year, representing a growth of approximately 3.67%[44] - Net profit for the current period was ¥110,846,716.74, an increase of 12.50% compared to ¥98,583,567.81 in the previous period[52] - The total comprehensive income for the current period was ¥110,846,716.74, up from ¥98,583,567.81, marking an increase of 12.50%[53] - The total profit for the current period was ¥123,525,587.96, compared to ¥113,951,829.02 in the previous period, indicating an increase of 8.00%[52] Assets and Liabilities - Total assets increased by 10.38% to ¥1,464,323,937.54 compared to the end of the previous year[7] - Current liabilities increased to CNY 359,504,644.49, up 22.3% from CNY 293,871,711.00[36] - Non-current liabilities totaled CNY 96,268,083.99, a slight increase from CNY 92,514,061.59[36] - The company's equity attributable to shareholders rose to CNY 1,008,551,209.06, up from CNY 940,294,710.77, reflecting a growth of 7.3%[37] - Total liabilities rose to CNY 354,925,361.37 from CNY 275,108,512.08, reflecting an increase of approximately 28.9%[43] - Total assets reached CNY 1,326,680,483.36, with current assets accounting for CNY 781,099,060.82[66] - Total liabilities amounted to CNY 386,385,772.59, with current liabilities at CNY 293,871,711.00[67] - Owner's equity totaled CNY 940,294,710.77, reflecting a strong capital position[68] Cash Flow - Net cash flow from operating activities increased by 13.64% to ¥85,733,001.44[7] - The net cash flow from operating activities increased by 14.59% to ¥180,331,100.39[21] - The net cash flow from operating activities for Q3 2020 was CNY 180,331,100.39, an increase of 14.5% compared to CNY 157,368,913.39 in Q3 2019[59] - Total cash inflow from operating activities was CNY 925,049,663.34, while cash outflow was CNY 744,718,562.95, resulting in a net cash inflow of CNY 180,331,100.39[59] - Cash flow from investment activities showed a net outflow of CNY 99,716,804.69, compared to a smaller outflow of CNY 48,887,818.04 in the previous year[60] - Cash flow from financing activities resulted in a net outflow of CNY 23,187,387.92, an improvement from a net outflow of CNY 43,587,552.01 in Q3 2019[63] Shareholder Information - The total number of shareholders at the end of the reporting period was 12,262[11] - The top two shareholders, Li Xi and Chen Xinmin, each hold 29.81% of the shares, totaling 59.62% combined[12] Expenses - Operating costs increased by 22.85% to ¥343,219,658.63, primarily due to rising material costs[19] - Sales expenses decreased by 27.86% to ¥355,007,060.98, attributed to reduced academic and brand promotion activities[19] - Research and development expenses were ¥71,292,858.21, down 11.67% from the previous period[19] - Research and development expenses remained stable at CNY 22,779,625.18 compared to CNY 22,974,860.89, indicating consistent investment in innovation[43] - The company reported a decrease in sales expenses to CNY 103,408,856.66 from CNY 153,941,926.89, a reduction of approximately 32.8%[43] Financial Position - Fixed assets increased significantly to CNY 481,865,367.60 from CNY 325,457,941.68, representing a growth of 47.9%[35] - Deferred tax assets increased by 45.61% to ¥13,603,601.33, mainly due to increased expenses from stock incentives[19] - The company reported a financial expense of ¥2,592,781.82, compared to a financial income of -¥226,891.69 in the previous period[52] Other Information - The company reported a government subsidy income of ¥12,678,160.22 during the period[8] - Non-recurring gains and losses totaled ¥12,276,041.72 for the year-to-date[8] - The company implemented new accounting standards for revenue recognition, enhancing financial transparency[68] - The company implemented the new revenue recognition standard starting in 2020, adjusting the presentation of contract liabilities[74] - The Q3 report was not audited[74]